NIH Licensing Opportunity:
Improving Efficacy of HIV Vaccines
One Million Solutions in Health™ has established a one-of-a-kind partnership with the United States’ National Institutes of Health Office of Technology Transfer (NIH-OTT) and the National Cancer Institute Technology Transfer Center (NCI-TTC) to increase awareness and understanding of NIH technologies by potential partners in the life science and healthcare industries.
This provides you with a front-row seat to hear about new technology and science from various scientists at the NIH. This is also your opportunity to participate in our proprietary Signature Square™ process, where end-users can evaluate the technology, ask questions and provide feedback directly to the scientist.
Increasing HIV Vaccine Efficacy
This webinar will incorporate three technologies that, when combined, result in a higher level of HIV vaccine efficacy:
The first technology (E-154-2000), uses the combination of a DNA prime and a recombinant pox virus boost together with an envelope protein boost. This particular pox virus expression vector enhances monocytes immune memory and CD4+T-cells; and synergize with the DNA prime to increase vaccine’s efficacy to 70%. This technology is used to create the second technology vaccine based gp120 having a deleted V1 region (i.e., V1 region deleted gp120 modified protein) the second technology described below.
The second technology (E-160-2018), is a V1 region deleted gp120 modified protein, that shows an increased response to the V2 region and superior vaccine efficacy.
The third technology (E-062-2014), demonstrates that increasing RAS activation results in increased vaccine efficacy. The thought here is to combine a RAS activation agent with the second technology’s V1 region deleted gp120 modified protein (E-160-2018) to further enhance the vaccine’s effectiveness.
This is an opportunity to LICENSE THIS TECHNOLOGY, or participate in further collaborative work to enhance its development.
The Signature Square process is part of our Consortium infrastructure. Current member companies in the Technology Evaluation Consortium and SafeTEC include organizations like AstraZeneca, AbbVie, Amgen and Allergan, along with many others, including scientists, clinicians and investors in organizations around the world who help to evaluate this technology.
This is your opportunity to ask questions and provide feedback directly to the scientists by taking part in this Signature Square program.
Genoveffa Franchini, M.D.
Head, Animal Models and Retroviral Vaccines Section
Dawn Van Dam
Executive Director & CEO
One Million Solutions in Health™